Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price & Analysis
Madrigal Pharmaceuticals, Inc. (MDGL) fell 0.28% to USD 541.08 as of September 8, 2026 at 05:00 UTC, according to Nexqual real-time market data.
MDGL last closed at USD 541.08; the session ranged USD 536.44–547.92 on volume of 177,171 shares. Market capitalization is —, with a 52-week range of USD 393.61–615 (NMS). Source: Nexqual, September 8, 2026 at 05:00 UTC.
Key Statistics (as of September 8, 2026 at 05:00 UTC)
| Price | USD 541.08 |
|---|---|
| Change | ▼ 0.28% (down) |
| Previous Close | USD 541.08 |
| Open | USD 541.08 |
| Day Range | USD 536.44 – 547.92 |
| 52-Week Range | USD 393.61 – 615 |
| Volume | 177,171 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (MDGL)
Nexqual's technical model rates MDGL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:00 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.34 (neutral) |
| vs SMA50 | Above (USD 529.59) |
| MACD | 5.47 (positive) |
From Madrigal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.
Partnerships
- In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.
- Blue Owl Credit Facility On July 17, 2025 (the "Closing Date"), we entered into the Financing Agreement with the Lenders and the Administrative Agent.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | USD 34.87 | ▲ 4.09% |
| AXSM | Axsome Therapeutics, Inc. | USD 206.68 | ▼ 1.54% |
| BBIO | BridgeBio Pharma, Inc. | USD 74.84 | ▼ 2.17% |
| KRYS | Krystal Biotech, Inc. | USD 358.24 | ▼ 2.98% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.74 | ▼ 2.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:00 UTC. This page is informational and not investment advice.